Is Mayne Pharma Group Ltd a buy after its stunning full year result?

Mayne Pharma Group Ltd (ASX:MYX) posts a stunning 379% increase in profit. Is it time you invested in this growth machine?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the most outstanding performers on the the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) in the last 12 months with a 76% gain has been the fantastic Mayne Pharma Group Ltd (ASX: MYX).

The market has been increasingly bullish on the growing Australian pharmaceutical company since it announced the US$652 million acquisition of a portfolio of drugs from industry giants Teva Pharmaceuticals and Allergan.

The blockbuster deal that closed earlier this month saw Mayne Pharma acquire 37 approved and five FDA filed products for less than 6x forecast FY 2017 EBITDA (that is, earnings before interest, taxes, depreciation and amortisation for the 2017 financial year). According to management the transaction is expected to launch the company into the top 25 retail generic pharmaceutical companies in the United States.

With these deals expected to be significantly accretive to earnings in FY 2017, Mayne Pharma's shareholders certainly have a lot to look forward to. Especially when you consider that the company has just reported a stunning FY 2016 result this morning that excludes the benefits of these acquisitions.

On the top line Mayne Pharma posted an 89% rise in full year revenue to $267.3 million. While that was undoubtedly strong, it will be the bottom line performance that steals the headlines. For FY 2016 the company reported a stunning 379% jump in net profit to $37.4 million.

The great result was driven by strong performances in all of Mayne Pharma's divisions, but most notably in its Generic Products Division. This segment's sales rose 84% to $106.8 million thanks partly to the launch of the BAC tablet and dofetilide products, as well as further market penetration by its oxycodone, hydrocodone, and methamphetamine products.

Net operating cash flow came in 139% higher year on year at $53.5 million after including $26.5 million of tax payments, a $6.7 million one-off settlement payment with a former distributor, and $8.1 million for transactions and other one-off costs.

With earnings per share coming in 302% higher at 4.6 cents, Mayne Pharma's shares are changing hands at approximately 42x full year earnings. Whilst this might seem expensive, I believe its explosive earnings growth potential more than justifies the premium.

In my opinion Mayne Pharma is right up there with the likes of fellow healthcare shares CSL Limited (ASX: CSL) and Ramsay Health Care Limited (ASX: RHC) as fantastic long-term buy and hold investments.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »